About: Early Experience with Arterial Thromboembolic Complications in Patents with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early Experience with Arterial Thromboembolic Complications in Patents with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Early Experience with Arterial Thromboembolic Complications in Patents with COVID-19
Creator	Billett, Henny Koleilat, Issam Aldailami, Hasan Choinski, Krystina Denesopolis, John Hatch, Ayesha Indes, Jeffrey Jones, Davis Lipsitz, Evan
Source	Elsevier; PMC
abstract	INTRODUCTION: Little is known about the arterial complications and hypercoagulability associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We sought to characterize our experience with arterial thromboembolic complications in patients with hospitalized for coronavirus disease 2019 (COVID-19). METHODS: All patients admitted from March 1 to April 20, 2020 and who underwent carotid, upper, lower and aortoiliac arterial duplex, CT angiogram or MRA for suspected arterial thrombosis were included. A retrospective case-control study design was used to identify, characterize and evaluate potential risk factors for arterial thromboembolic disease in SARS-CoV-2 positive patients. Demographics, characteristics and laboratory values were abstracted and analyzed. RESULTS: During the study period, 424 patients underwent 499 arterial duplex, CT angiogram or MRA imaging studies with overall 9.4% positive for arterial thromboembolism. Of the 40 patients with arterial thromboembolism, 25 (62.5%) were SARS-CoV-2 negative or admitted for unrelated reasons and 15 (37.5%) were SARS-CoV-2 positive. The odds ratio for arterial thrombosis in COVID-19 was 3.37 (95% CI 1.68 – 6.78, p=0.001). Although not statistically significant, in patients with arterial thromboembolism, patients who were SARS-CoV-2 positive compared to those testing negative or not tested tended to be male (66.7 % v. 40.0%, p=0.191), have a less frequent history of former or active smoking (42.9% vs 68.0%, p=0.233) and have a higher white blood cell count (WBC 14.5 vs. 9.9, p=0.208). While the SARS-CoV-2 positive patients trended toward a higher the neutrophil-to-lymphocyte ratio (8.9 vs. 4.1, p=0.134), CPK level (359.0 vs. 144.5, p=0.667), CRP level (24.2 vs. 13.8, p=0.627), LDH level (576.5 vs. 338.0, p=0.313) and ferritin level (974.0 vs. 412.0, p=0.47), these did not reach statistical significance. Patients with arterial thromboembolic complications and SARS-CoV-2 positive when compared to SARS-CoV-2 negative or admitted for unrelated reasons were younger (64 vs. 70 years, p=0.027), had a significantly higher body mass index (BMI) (32.6 vs. 25.5, p=0.012), a higher D-dimer at the time of imaging (17.3 vs. 1.8, p=0.038), a higher average in hospital D-dimer (8.5 vs. 2.0, p=0.038), a greater distribution of patients with clot in the aortoiliac location (5 vs. 1, p=0.040), less prior use of any antiplatelet medication (21.4% vs. 62.5%, p=0.035) and a higher mortality rate (40.0 % vs. 8.0%, p=0.041). Treatment of arterial thromboembolic disease in the COVID-19 positive patients included open thromboembolectomy in 6 patients (40%), anticoagulation alone in 4 (26.7%) and 5 (33.3%) did not require or their overall illness severity precluded additional treatment. CONCLUSIONS: Patients with SAR-CoV-2 are at risk for acute arterial thromboembolic complications despite a lack of conventional risk factors. A hyperinflammatory state may be responsible for this phenomenon with a preponderance for aortoiliac involvement. These findings provide an early characterization of arterial thromboembolic disease in SARS-CoV-2 patients.
has issue date	2020-08-28(xsd:dateTime)
bibo:doi	10.1016/j.jvs.2020.07.089
has license	no-cc
sha1sum (hex)	a105ffe0b3b61fb3a87bc85e3acf043af7e0163a
schema:url	https://doi.org/10.1016/j.jvs.2020.07.089
resource representing a document's title	Early Experience with Arterial Thromboembolic Complications in Patents with COVID-19
has PubMed Central identifier	PMC7452862
schema:publication	J Vasc Surg
resource representing a document's body	covid:a105ffe0b3b61fb3a87bc85e3acf043af7e0163a#body_text
is schema:about of	named entity 'Complications' named entity 'Arterial' named entity 'Surgery' named entity 'Journal' named entity 'Associate Professor' named entity 'BMI' named entity 'virus' named entity 'thrombotic events' named entity 'COVID-19' named entity 'magnetic resonance angiography' named entity 'white blood cell count' named entity 'emboli' named entity 'SARS-CoV' named entity 'BMI' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'antibody tests' named entity 'neutrophil to lymphocyte ratio' named entity 'informed consent' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'MRA' named entity 'Retrospective chart review' named entity 'SARS-CoV-2' named entity 'arterial thrombosis' named entity 'statistical significance' named entity 'medical record' named entity 'thrombosis' named entity 'mmHg' named entity 'triglyceride' named entity 'virus' named entity 'SARS-CoV-2' named entity 'ethnicity' named entity 'neurologic' named entity 'thromboembolic' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'Fisher's exact test' named entity 'CTA' named entity 'demographic' named entity '14.5' named entity 'HDL' named entity 'SARS-CoV-2' named entity 'BMI' named entity 'SARS-CoV-2' named entity 'MRA' named entity 'SARS-CoV-2' named entity 'mmHg' named entity 'body mass' named entity 'SARS-CoV-2' named entity 'stroke' named entity 'Amputation' named entity 'polymerase chain reaction' named entity 'SARS-CoV-2' named entity 'statistical significance' named entity 'data abstraction' named entity 'platelet count' named entity 'False negative' named entity 'carotid duplex' named entity 'initial testing' named entity 'Nasopharyngeal swab' named entity 'PCR' named entity 'SARS-CoV-2' named entity 'acute arterial ischemia' named entity 'thrombosis' named entity 'systolic blood pressure' named entity 'imaging modality' named entity 'infection' named entity '8.5' named entity 'SARS CoV' named entity 'skilled nursing facilities' named entity 'serum glucose' named entity 'inflammation' named entity 'diastolic' named entity 'develop immunity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software